Furthermore, Pan et al. [62] analyzed 34 studies with 12,682 participants and found that PPS therapies improved hepatic fibrosis (SMD = −0.31; 95% CI: −0.53, −0.09), AST (SMD = −0.35; 95% CI: −0.55, −0.15) and ALT levels (SMD = −0.48; 95% CI: −0.71, −0.25), and inflammatory markers like TNF-α (SMD = −0.86; 95% CI: −1.56, −0.56). This evidence concerns the gene GPT and Hepatic fibrosis.